XERS Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Xeris Biopharma Holdings Inc - Alpha Spread

Xeris Biopharma Holdings Inc
NASDAQ:XERS

Watchlist Manager
Xeris Biopharma Holdings Inc Logo
Xeris Biopharma Holdings Inc
NASDAQ:XERS
Watchlist
Price: 2.98 USD
Market Cap: 441.8m USD
Have any thoughts about
Xeris Biopharma Holdings Inc?
Write Note

Wall Street
Price Targets

XERS Price Targets Summary
Xeris Biopharma Holdings Inc

Wall Street analysts forecast XERS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for XERS is 4.76 USD with a low forecast of 3.03 USD and a high forecast of 6.3 USD.

Lowest
Price Target
3.03 USD
2% Upside
Average
Price Target
4.76 USD
60% Upside
Highest
Price Target
6.3 USD
111% Upside

XERS Last Price Targets
Xeris Biopharma Holdings Inc

The latest public price target was made on May 10, 2024 by David Amsellem from Piper Sandler , who expects XERS stock to rise by 1% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
David Amsellem
Piper Sandler
3 USD
Upside 1%
4 months ago
May 10, 2024
Xeris Pharmaceuticals (XERS) PT Lowered to $3 at Piper Sandler
StreetInsider
David Amsellem
Piper Sandler
Price Target 3 USD
Upside/Downside 1%
View Source
Xeris Biopharma Holdings Inc Competitors:
Price Targets
ZYDUSLIFE
Zydus Lifesciences Ltd
12% Upside
MDWD
Mediwound Ltd
81% Upside
603998
Hunan Fangsheng Pharmaceutical Co Ltd
26% Upside
COPN
Cosmo Pharmaceuticals NV
30% Upside
326030
SK Biopharmaceuticals Co Ltd
6% Upside
JUBLPHARMA
Jubilant Pharmova Ltd
5% Upside
WVE
WAVE Life Sciences Ltd
67% Upside
2096
Simcere Pharmaceutical Group Ltd
18% Upside

Revenue
Forecast

Revenue Estimate
Xeris Biopharma Holdings Inc

For the last 6 years the compound annual growth rate for Xeris Biopharma Holdings Inc's revenue is 116%. The projected CAGR for the next 3 years is 19%.

116%
Past Growth
19%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Xeris Biopharma Holdings Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat

Net Income
Forecast

Net Income Estimate
Xeris Biopharma Holdings Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-55%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is XERS's stock price target?
Price Target
4.76 USD

According to Wall Street analysts, the average 1-year price target for XERS is 4.76 USD with a low forecast of 3.03 USD and a high forecast of 6.3 USD.

What is Xeris Biopharma Holdings Inc's Revenue forecast?
Projected CAGR
19%

For the last 6 years the compound annual growth rate for Xeris Biopharma Holdings Inc's revenue is 116%. The projected CAGR for the next 3 years is 19%.

Back to Top